Furthermore, we identified the key bioactive compounds in ECT (Sachaliside, Naringenin, Liquiritigenin, maclurin, and Rhapontigenin) and elucidated its underlying LPS‐TLR4/MyD88/NF‐κB signaling pathway in mitigating obesity‐induced oxidative stress and inflammatory responses. The gene discussed is MYD88; the disease is obesity disorder.